Stocktwits on MSN
ANRO stock drops 7% after disappointing schizophrenia study results – but analyst sees dip as attractive entry point
H.C. Wainwright said the failure of ALTO-101 in its Phase 2 study does not change its overall view on Alto Neuroscience. ・Baird cut Alto’s price target to $38 from $41 but said the company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results